Chen, Po-YuPo-YuChenChiu, Chih-ChiangChih-ChiangChiuCHIN-KUO CHANGLu, Mong-LiangMong-LiangLuHuang, Cho-YinCho-YinHuangChen, Chun-HsinChun-HsinChenHuang, Ming-ChyiMing-ChyiHuang2024-03-222024-03-222024-0302698811https://scholars.lib.ntu.edu.tw/handle/123456789/641250Clozapine is the primary antipsychotic (APD) for treatment-resistant schizophrenia (TRS). However, only 40% of patients with TRS respond to clozapine, constituting a subgroup of clozapine-resistant patients. Recently, the neuropeptide orexin-A was shown to be involved in the pathophysiology of schizophrenia. This study evaluated the association of orexin-A levels with the clozapine response in patients with TRS.enClozapine; Cognition; Orexin-A; Treatment response; Treatment-resistant schizophreniajournal article10.1177/02698811231225610382796712-s2.0-85183883863https://api.elsevier.com/content/abstract/scopus_id/85183883863